Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Stereoselective Inhibition Of Inducible Cyclooxygenase By Chiral Nonsteroidal Antiinflammatory Drugs
A. Carabaza, F. Cabré, E. Rotllan, M. Gómez, M. Gutiérrez, M. L. Garcia, D. Mauleón
Published 1996 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The stereoselective inhibition of inducible cyclooxygenase (COX‐2) by chiral nonsteroidal antiinflammatory drugs (NSAIDs)—ketoprofen, flurbiprofen, and ketorolac—has been investigated. The activity and inhibition of COX‐2 was assessed in three different in vitro systems: guinea pig whole blood, lipopolysaccharide (LPS)‐stimulated human monocytes, and purified preparations of COX‐2 from sheep placenta. The results were compared with the inhibition of constitutive cyclooxygenase (COX‐1) in three parallel in vitro models: clotting guinea pig blood, human polymorphonuclear leukocytes, and purified COX‐1 from ram seminal vesicles. In the whole blood model, both isoenzymes were inhibited by S‐enantiomers with equal potency but S‐ketoprofen was the most active on COX‐2 (IC50 = 0.024 μmol/L). In contrast, both isoenzymes were inhibited less than 40% by all three R‐enantiomers at high concentration (>1 μmol/L). The inhibition of COX by the R‐enantiomers may be attributed to contamination with the S‐enantiomers (approximately 0.5%). A significant degree of enantioselectivity in COX‐2 inhibition was also observed in intact cells. The S‐enantiomers inhibited COX‐2 from monocytes with IC50 values in the range of 2 to 25 nmol/L, being 100 to 500‐fold more potent than the corresponding R‐enantiomers. Finally, S‐ketoprofen inhibited COX‐2 from sheep placenta (IC50 = 5.3 μmol/L) with slightly less potency than S‐ketorolac (IC50 = 0.9 μmol/L) and S‐flurbiprofen (IC50 = 0.48 μmol/L), whereas the R‐enantiomers were found to be essentially inactive (IC50 ≥ 80 μmol/L). It is concluded that the chiral NSAIDs studied here inhibit with comparable stereoselectivity both COX‐2 and COX‐1 isoenzymes, and that the inhibition of COX‐2 previously observed for racemic NSAIDs should be attributed almost exclusively to their S‐enantiomers.
This paper references
Selective inhibition of cyclooxygenase 2.
T. Klein (1994)
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.
K. Seibert (1994)
Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase.
R. A. Copeland (1994)
Enzymatic inversion at saturated carbon: nature and mechanism of the inversion of R(-) p-iso-butyl hydratropic acid.
W. Wechter (1974)
Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994;48:16051610
T Klein (1994)
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
J. Masferrer (1994)
Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen.
A. Evans (1991)
Pharmacological aspects of chiral nonsteroidal anti‐inflammatory drugs
N. Muller (1990)
Absolute Configuration of (-)-5-Benzoyl-1,2-dihydro-3H-pyrrolo[l,2-a]pyrrole-1-carboxylic Acid, the Active Enantiomer of Ketorolac.
A. Guzmán (1986)
Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells.
J. A. Maier (1990)
Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs.
O. Laneuville (1994)
Comparison of recombinant cyclooxygenase‐2 to native isoforms: aspirin labeling of the active site
L. Wennogle (1995)
Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms.
M. Ouellet (1995)
NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.
N. Futaki (1994)
Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs.
E. Meade (1993)
Separation of mixtures of enantiomers of arylpropionic acids. German Patent DE 3824353 A1
H Lukas (1990)
Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation.
J. Vane (1994)
NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.
N. Futaki (1993)
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects.
C. Patrono (1980)
Inflammation and the mechanism of action of anti‐inflammatory drugs
J. Vane (1987)
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases.
P. Patrignani (1994)
Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs.
W. Smith (1995)
Protein Binding and Stereoselectivity of Nonsteroidal Anti-Inflammatory Drugs
F. Lapicque (1993)
Lipopolysaccharide induces bovine aortic endothelial cells to synthesize COX, but not nitric oxide synthase: a comparison with macrophages
P Akarasereenont (1994)
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-l
D Picot (1994)
Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen.
N. Suesa (1993)
popolysaccharide induces bovine aortic endothelial cells to synthesize COX , but not nitric oxide synthase : a comparison with macrophages ( abstract )
P Akarasereenont (1994)
The (+)-eoan511 CARABAZA ET AL tiomer is responsible for the antiplatelet and anti-inflammatory activity of (±)-indobufen
C Cerletti (1990)
Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis.
T. Shimokawa (1990)
The isoforms of cyclooxygenase: structure and fuction
PJ Loll (1994)
Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro.
M. Villanueva (1993)
Effects of the novel anti‐inflammatory compounds, N‐[2‐(cyclohexyloxy)‐4‐nitrophenyl] methanesulphonamide (NS‐398) and 5‐methanesulphonamido‐6‐(2, 4‐difluorothiophenyl)‐1‐indanone (L‐745, 337), on the cyclo‐oxygenase activity of human blood prostaglandin endoperoxide synthases
Maria R. Panara (1995)
Stereoisomeric relationships among anti-inflammatory activity, inhibition of platelet aggregation, and inhibition of prostaglandin synthetase.
Z. Gaut (1975)
Inhibition of prostaglandin synthase by pirprofen. Studies with sheep seminal vesicle enzyme.
E. Ku (1975)
Effects of pure enantiomers of flurbiprofen in comparison to racemic flurbiprofen on eicosanoid release from various rat organs ex vivo.
B. M. Peskar (1991)
Biological activity of indoprofen and its optical isomers
A. Buttinoni (1983)
The (+)‐enantiomer is responsible for the antiplatelet and anti‐inflammatory activity of (±)‐indobufen
C. Cerletti (1990)
Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood.
P. Patrignani (1990)
Absolute configuration of (-)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-alpha]pyrrole-1-carboxylic acid, the active enantiomer of ketorolac.
A. Guzmán (1986)
Tyrosine 385 of prostaglandin synthase is required for cyclooxygenase catalysis
T Shimokawa (1992)
Biochemistry of protaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs
WL Smith (1995)
Enantioselective pharmacodynamics of the nonsteroidal antiinflammatory drug ketoprofen: in vitro inhibition of human platelet cyclooxygenase activity.
P. Hayball (1992)
Inhibition of prostaglandin synthesis by sodium 2-[4-(2-oxocyclopentylmethyl)phenyl] propionate dihydrate (CS-600), a new anti-inflammatory drug, and its active metabolite in vitro and in vivo.
K. Matsuda (1984)
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
D. Picot (1994)
Lipopolysaccharide induces bovine aortic endothelial cells to synthesize COX, but not nitric oxide synthase: a comparison with macrophages (abstract)
P Akarasereenont (1994)
Separation of mixtures of enantiomers of arylpropionic acids
H Lukas (1990)
NSAIDs: An Overview
C. S. Boynton (1988)
Mitogen‐inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs
W. Xie (1992)
Resolution of rac‐ketoprofen esters by enzymatic reactions in organic media
A. Palomer (1993)
Drug Chirality: On the Mechanism of R‐Aryl Propionic Acid Class NSAIDs. Epimerization in Humans and the Clinical Implications for the Use of Racemates
W. Wechter (1994)
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase.
J. Mitchell (1993)
Isolation of mononuclear cells and granulocytes from human blood.
A. Bøyum (1968)
[The inhibitory activities of 480156-S and its related compounds on prostaglandin synthetase].
T. Yamaguchi (1987)
Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.
C. Chan (1995)
This paper is referenced by
Comparison of the Efficacy and Tolerability of Dexketoprofen and Ketoprofen in the Treatment of Primary Dysmenorrhea
M. Ezcurdia (1998)
Peripheral and/or central effects of racemic‐, S(+)‐ and R(−)‐flurbiprofen on inflammatory nociceptive processes: a c‐Fos protein study in the rat spinal cord
J. Buritova (1998)
Adenosine A2A Receptors in the Nucleus Accumbens Bi-Directionally Alter Cocaine Seeking in Rats
C. O’Neill (2012)
Analgesic Effect of the Newly Developed S(+)‐Flurbiprofen Plaster on Inflammatory Pain in a Rat Adjuvant‐Induced Arthritis Model
M. Sugimoto (2016)
Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.
A. Palomer (2002)
Physiologic Rationale, Diagnostic Implications, and Clinical Consequences
Karen I. Plaisance (2016)
Mechanism of Enhancement of Intestinal Ulcerogenicity of S-Aryl Propionic Acids by Their R-Enantiomers in the Rat
W. Wechter (2004)
Flurbiprofen and enantiomers in ophthalmic solution tested as inhibitors of prostanoid synthesis in human blood.
N. J. V. Haeringen (2000)
S(+)-Flurbiprofen Shows Potent PGE2 Inhibitory Activity in Inflammatory Cells, Superior Cell Transport Activity and Skin Permeability
Y. Toda (2016)
Analgesic effect of S (+)‐flurbiprofen plaster in a rat model of knee arthritis: analysis of gait and synovial fluid prostaglandin E2 levels
Ayaka Fukumoto (2018)
Comparison of Tissue Concentrations After Intramuscular and Topical Administration of Ketoprofen
I. Tegeder (2004)
Evidence for a central mechanism of action of S-(+)-ketoprofen.
M. I. Díaz-Reval (2004)
Effects of distinct populations of adenosine receptors in the ventral striatum on cocaine seeking
C. O’Neill (2015)
Ketoprofen S(+) enantiomer inhibits prostaglandin production and cell growth in 3T6 fibroblast cultures.
T. Sánchez (1999)
Efficacy of S-flurbiprofen plaster in knee osteoarthritis treatment: Results from a phase III, randomized, active-controlled, adequate, and well-controlled trial
I. Yataba (2017)
R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer's disease
I. Carreras (2013)
Effect of arachidonic and eicosapentaenoic acid metabolism on RAW 264.7 macrophage proliferation
D. Nieves (2006)
Synthesis and prostaglandin synthase inhibitory activity of new aromatic O-alkyloxime ethers substituted with methylsulfonamido or methylsulfonyl groups on their aliphatic portion.
A. Balsamo (2003)
Ketoprofen-Induced Cyclooxygenase Inhibition in Renal Medulla and Platelets of Rats Treated with Caffeine
M. Sommerauer (2001)
Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans
I. Yataba (2015)
Enantiomers of flurbiprofen can distinguish key pathophysiological steps of NSAID enteropathy in the rat
T. Mahmud (1998)
Effect of NSAID administration on tissue levels of immunoreactive prostaglandin E2, leukotriene B4, and (S)-flurbiprofen following extraction of impacted third molars
M. Roszkowski (1997)
Preclinical and Clinical Development of Dexketoprofen
Dr David Mauleón (2012)
Ketoprofen 2.5% gel: a clinical overview.
S. Coaccioli (2011)
L-Type Amino Acid Transporter 1 (LAT1)-Utilizing Prodrugs Are Carrier-Selective Despite Having Low Affinity for Organic Anion Transporting Polypeptides (OATPs).
J. Huttunen (2019)
Pharmacokinetics and Pharmacodynamics of (S)-Ketoprofen Co-Administered with Caffeine: A Preclinical Study in Arthritic Rats
R. Medina-López (2018)
Dexketoprofen-induced antinociception in animal models of acute pain: Synergy with morphine and paracetamol
H. Miranda (2007)
Analgesic Efficacy and Safety of (R)‐ Ketoprofen in Postoperative Dental Pain
S. Cooper (1998)
Dexketoprofen trometamol in post-operative pain management
Daniel Burke (2003)
Involvement of serotonin mechanisms in the antinociceptive effect of S(+)‐ketoprofen
M. I. Díaz-Reval (2002)
(S)-ketoprofen accumulation in premature neonates with renal failure who were exposed to the racemate during pregnancy.
B. Bannwarth (1999)
Bioinversion of R-flurbiprofen to S-flurbiprofen at various dose levels in rat, mouse, and monkey.
D. D. Leipold (2004)See more